Antiplatelet Therapy in Patients on Heparin Drip

Core Principle: Heparin Plus Antiplatelet Therapy is Standard

The American Heart Association recommends that heparin is always used in combination with aspirin in acute coronary syndromes, reducing cardiovascular death and myocardial infarction by approximately 30% compared to aspirin alone 1, 2
The combination of heparin plus aspirin reduces the incidence of myocardial infarction from 11.9% (placebo) to 1.6% in patients with unstable angina, demonstrating clear mortality and morbidity benefit 1, 2
Heparin is no longer used as sole antithrombotic therapy in acute coronary syndromes and is always combined with aspirin in patients with acute myocardial ischemia, those receiving thrombolytic therapy, those treated with GP IIb/IIIa antagonists, and those undergoing high-risk coronary angioplasty 1, 2

When heparin is combined with thrombolytic agents or GP IIb/IIIa antagonists, the heparin dose is usually reduced (not the antiplatelet therapy discontinued) to manage increased bleeding risk 1, 2

Unfractionated heparin is associated with higher cardiac complication rates compared to low molecular weight heparin in patients with coronary stents, likely due to "heparin rebound" - a period of hypercoagulability after abrupt cessation 3, 4

Abrupt cessation of unfractionated heparin causes increased thrombin activity and platelet activation that persist for many hours after cessation, while protective anticoagulant effects decline rapidly due to heparin's short half-life 3, 4
Ischemic events cluster around a median time of 9.5 hours after cessation of unfractionated heparin in patients with acute coronary syndromes 3, 4
Low molecular weight heparin, which has a longer half-life and does not activate platelets, is not associated with increased ischemic events and should be considered the preferred agent if heparin bridging is needed 3, 4

In patients with suspected HIT and an intermediate-probability 4Ts score who have another indication for therapeutic-intensity anticoagulation, continuation of heparin is recommended until HIT testing is completed 5, 6
In patients with suspected HIT and a high-probability 4Ts score, heparin should be discontinued and a non-heparin anticoagulant initiated at therapeutic intensity 5, 6

Do not abruptly discontinue unfractionated heparin without considering the rebound hypercoagulability risk, especially in patients with acute coronary syndromes 3, 4
Do not hold antiplatelet therapy simply because a patient is on heparin - the combination is often intentional and evidence-based for reducing cardiovascular events 1, 2